Maxim upgraded Reviva Pharmaceuticals (RVPH) to Buy from Hold with a $7 price target The company has taken steps to address its financing overhang, raising $18M in gross proceeds on December 16 and funding the company through the upcoming full data from its open-label extension study as well as the planned launch of RECOVER-2, the analyst tells investors in a research note. The upgrade also reflects Reviva’s de-risking of preliminary data from the OLE study as the company prepares to get the second Phase 3 study going after the first “successful” de-risking Phase 3 trial, Maxim adds.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVPH:
- Reviva Pharmaceuticals upgraded to Buy from Hold at Maxim
- Reviva Pharmaceuticals initiated with a Buy at Roth MKM
- Reviva Pharmaceuticals Strengthens Financial Position with Offering
- Reviva Pharmaceuticals 12M share Spot Secondary priced at $1.50
- Reviva Pharmaceuticals announces common stock, warrant offering, no amount given